Acthar's Future Could Be An Adverse Event For Mallinckrodt

|
About: Mallinckrodt plc (MNK)
by: Ikarian Point Research
This article is exclusive for subscribers.
Ikarian Point Research
Long/short equity, value, special situations, contrarian
Summary

Recent revelations demonstrate that QCOR's drug Acthar was administered to patients who suffered hundreds of adverse events and several deaths.

Adverse events related to Acthar occur predominately in NS patients. A real safety study is needed as no large-scale study on NS patients has ever been performed.

QCOR's clinical trial results to-date leave much to be desired. Efficacy and safety are questionable. This may become a serious issue for MNK post-merger.

In a Seeking Alpha blog post last October we brought to light shady practices of the Chronic Disease Fund (CDF) as well as Questcor Pharmaceuticals' (NASDAQ:QCOR) all-too-cozy relationship with the charity. Since then, the CDF